Skip to content

SOTIO has stopped collaboration trial with the dendritic cell vaccine DCVAC in combination with ONCOS-102

Oslo, Norway, 9 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that collaboration partner SOTIO has stopped the combination trial assessing the combination of ONCOS-102 and DCVAC/PCa in prostate cancer. Only a very limited patient population fulfilled the strict inclusion criteria. Therefore, the recruitment could not meet originally planned numbers.

The phase I trial prostate cancer study was paid for and run by the Czech biotech company SOTIO, investigating whether ONCOS-102 could enhance the efficacy of SOTIO´s dendritic cell vaccine DCVAC/PCa. Targovax has generated promising data in melanoma and mesothelioma, and the decision will not impact the further development of ONCOS-102.

Patient recruitment has been slow due to limited patient population availability. In combination with additional COVID-19 related challenges, SOTIO has decided to stop the trial after four patients enrolled. This was a phase I safety trial, and an analysis of clinical outcomes will be submitted at a future scientific conference.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773

IR enquires:
Kim Sutton Golodetz – LHA Investor Relations (US)
Phone: +1 212-838-3777
About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. The Group’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile. Further, the products are well positioned for combinations with other treatment approaches, including other immunotherapies, surgery, radiation and chemotherapy.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and colorectal cancer and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Source: Targovax